Neurological Manifestations of COVID-19 patients: An Updated Review and Observations of COVID Patients in the National Institute of Neurosciences and Hospital, Dhaka, Bangladesh

ME HUSSAIN\textsuperscript{a}, MA HOQUE\textsuperscript{b}, MB ALAM\textsuperscript{c}, MA YUSUF\textsuperscript{d}, RN CHOWDHURY\textsuperscript{e}, QD MOHAMMAD\textsuperscript{f}

Summary:
Involvement of the nervous system after viral infection is common. Certain viruses show neurotropism. Recent outbreak of severe acute respiratory syndrome CoV 2 (SARS-CoV-2) virus has also exhibited neurotropic properties with various neurological manifestations. The pathophysiology of their neurotropism is not yet clearly known. The details of pathophysiology, clinical manifestation and management are expected to be explored in the near future. Here we review the neurological manifestations of COVID-19 and the early experience in the National Institute of Neurosciences and Hospital.

Keywords COVID-19, Neurological manifestation, Stroke, Encephalitis, GBS

Conflict of interest: None. Contribution of authors: MEH was involved in writing the manuscript, AH was involved in supervision, planning and manuscript revision, BA and RNC were involved in the revision of the manuscript, MAY helped in statistical analysis and data collection, QDM was the supervisor and guide.

Introduction:
Corona virus disease 2019 (COVID-19) caused by SARS-Cov-2 virus, first emerged from Wuhan city, Hubei province of China\textsuperscript{1,2}. The World health organization (WHO) China Country Office on 31 December 2019, was informed of cases of pneumonia of unknown etiology\textsuperscript{3} which on 11\textsuperscript{th} March 2020 was declared as a pandemic by WHO\textsuperscript{4}. Since the detection COVID-19, hundreds of manuscripts have been published on the disease in different journals\textsuperscript{5}. With the progression of time numerous data on different aspects of the disease such as manifestations, pathology, transmission, prevention, and management strategies have started to emerge\textsuperscript{6,7,8}. Although initially it was thought to involve primarily the respiratory system like other coronaviruses, e.g. severe acute respiratory syndrome (SARS) and the Middle East Respiratory Syndrome (MERS), later it was found to have involved other systems as well including the nervous system\textsuperscript{9,10}.

This article contains a descriptive review of the neurological manifestations and complications of COVID-19 with an aim to update the neurologists and physicians working with suspected cases of COVID-19 infection.

Medline, PubMed Central and Google Scholar using keywords “COVID-19”, “Coronavirus”, “SARS-CoV-2”, “Neurology”, “Neurological”, “complications” and “manifestations” were searched and was limited only to English language manuscripts with no time limit. It consists mostly of pre-prints, case reports, small case series, and part of an article describing clinical features of COVID-19 and some review articles as well.
Pathogenesis
Mechanism of involvement of the nervous system
Corona viruses, especially SARS-CoV-2, which the SARS-CoV-2 belongs are not primarily neurotropic, rather their primary target is respiratory epithelium. The target receptor for attachment to cell and subsequent internalization is through the angiotensin converting enzyme-2 receptor (ACE 2) located abundantly in lung alveolar epithelial cells, enterocytes of the small intestine, arterial and venous endothelial cells and arterial smooth muscle cells in all organs. After entry into the cell the virus RNA is released in the cytoplasm which is subsequently translated and replicated. After formation of envelope protein and incorporation of RNA into the virus it is released in the circulation. ACE 2 receptors are also found in the neurons and glial cells in brain and spinal cord. These receptors are abundant in the brain stem and in the regions responsible for regulation of cardiovascular function including subfornical organ, paraventricular nucleus, nucleus of the tractus solitarius, and rostral ventrolateral medulla. So the virus can attach, multiply and damage the neuronal tissue. There are several postulated mechanisms. Firstly, experiments in mice showed that the coronavirus enters the brain through a retrograde transfer via the olfactory epithelium or through the cribiform bone and reaches the brain in seven days' time. Secondely, during the viremia phase of illness, disruption of blood brain barrier causes the virus to enter the brain directly. Thirdly, the invasion of peripheral nerve terminals by CoV which then gains entry to the CNS through the synapse connected route. Since COVID-19 has similarities with Severe Acute Respiratory Syndrome (SARS CoV), it is presumed that it also follows the same pathways for CNS invasion as discussed above.

Mechanism of damage to the nervous system:
Two mechanisms have been implicated for neurological damage. Firstly, severe pneumonia causes systemic hypoxia resulting in neuronal swelling and brain edema which ultimately results in neurological damage. The contributory factors here are peripheral vasodilatation, hypercarbia, hypoxia and anaerobic metabolism with accumulation of toxic compounds. If the hypoxia continues unabated, cerebral edema and the cerebral circulation disorder may worsen sharply. With intracranial hypertension, the brain function gradually deteriorates resulting in drowsiness, bulbar conjunctival edema, and even coma. In addition, for patients at particular risk of developing cerebrovascular disease, hypoxia may also induce the occurrence of acute cerebrovascular disease such as acute ischemic stroke. Secondly, cytokine storms with increased levels of inflammatory cytokines and activation of T lymphocytes, macrophages, and endothelial cells lead to immune mediated injury. Hypercytokinemia causes vascular leakage, activation of complement and coagulation cascade, disseminated intravascular coagulation and end organ damage.

Neurological manifestations
Most of the knowledge about neurological manifestations of COVID-19 so far gained, largely comes from few case series from China and one ICU-based observational study from France along with some individual case reports. The important neurological manifestations and complications of COVID-19 reported in literature so far are summarized in Fig 1. There are 2 case series specifically describing neurological manifestations and complications in COVID-19 patients (Table 1). The first is a retrospective case series on neurological manifestation from China by Mao et al. They reported the patients in two groups. The severely ill group had 88 (41.1%) patients while there were 126 (58.9%) patients in the non-severely ill group. Patients in the severely ill group were significantly older (58.2 ± 15 vs. 48. 9 ± 14.7 years) with more co-morbid conditions especially hypertension (36.4% vs. 19 (15.1$\%)). Surprisingly the severely ill group had less typical symptoms of coronavirus like fever (40 (45.5%) vs. 92 (73%)) and dry cough [30 (34.1%) vs. 77 (61.1%)]. However, nervous system symptoms were significantly more common in severe cases as compared with non-severe cases [40 (45.5%) vs. 38 (30.2%)]. The most common CNS symptoms reported were dizziness [36 (16.8%) and headache [28 (13.1%)].

The second article is a prospective case series of 58 patients from France. The median age of patients was 63 years and neurological complications were seen in a higher percentage 49/58 (84%). As assessed by confusion Assessment method for intensive care unit CAM-ICU scale, agitation was the most common symptoms 40/58 (69%) followed by confusion 26/40 (65%). Corticospinal tract signs were present in in 39/58 (67%) and a dysexecutive syndrome at the time of discharge was noted in14/39 (36%).
Table-I

Comparison of Neurological complications and manifestations between the severely ill Chinese and French patient series.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mao et al. (^{17})</th>
<th>Helms et al. (^{19})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design</td>
<td>Retrospective Chart Review</td>
<td>Prospective Observational study</td>
</tr>
<tr>
<td>Total Number of cases</td>
<td>214</td>
<td>58</td>
</tr>
<tr>
<td>Number of seriously ill patients</td>
<td>88</td>
<td>58</td>
</tr>
<tr>
<td>Median Age (Years)</td>
<td>58.7</td>
<td>63</td>
</tr>
<tr>
<td>Neurological Involvement</td>
<td>45.5%</td>
<td>84%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>19.3%</td>
<td>NR</td>
</tr>
<tr>
<td>Headache</td>
<td>17.1%</td>
<td>NR</td>
</tr>
<tr>
<td>Impaired consciousness</td>
<td>14.8%</td>
<td>NR</td>
</tr>
<tr>
<td>Hypogeusia</td>
<td>5.6%</td>
<td>NR</td>
</tr>
<tr>
<td>Hyposmia</td>
<td>5.1%</td>
<td>NR</td>
</tr>
<tr>
<td>Skeletal muscle injury</td>
<td>19.3%</td>
<td>NR</td>
</tr>
<tr>
<td>Simplified Acute Physiology Score II</td>
<td>NR</td>
<td>52</td>
</tr>
<tr>
<td>Agitation</td>
<td>NR</td>
<td>40 (69%)</td>
</tr>
<tr>
<td>Delirium as documented by CAM-ICU</td>
<td>NR</td>
<td>26 (65%)</td>
</tr>
<tr>
<td>Corticospinal tract signs</td>
<td>NR</td>
<td>39 (67%)</td>
</tr>
<tr>
<td>Dysexecutive syndrome at discharge</td>
<td>NR</td>
<td>14 (36%)</td>
</tr>
<tr>
<td>Ischemic stroke</td>
<td>5 (5.7%)</td>
<td>3/13 (23%)</td>
</tr>
<tr>
<td>Hemorrhagic Stroke</td>
<td>1 (1.13)</td>
<td>Nil</td>
</tr>
<tr>
<td>Leptomeningeal enhancement on MRI</td>
<td>NR</td>
<td>8/13 (62)</td>
</tr>
<tr>
<td>EEG</td>
<td>NR</td>
<td>1(8) diffuse bifrontal slowing</td>
</tr>
</tbody>
</table>

Fig.-1: Summary of major neurological abnormalities in COVID-19

Covid-19 and Major Reported Neurological Abnormalities

Central Nervous System (Mostly inflammation-mediated)
- Headache
- Dizziness
- Seizures
- AMS
- Delirium
- CVA (both ischemic and hemorrhagic)
- Infectious Toxic Encephalopathy
- Acute Encephalitis
- Meningitis
- Dysexecutive syndrome
- Acute Myelitis

Peripheral Nervous System (Mostly immune-mediated)
- Dysosmia/Anosmia
- Dysgeusia/ageusia
- GBS
- Miller Fisher Syndrome
- Polyneuritis Cranialis

Musculoskeletal (Direct Injury)
- Atonia
- Paresis
Central nervous system manifestations:

Encephalopathy:
Mao et al\textsuperscript{17} reported headache and encephalopathy in 40\% of patients in their cohort but the details and the diagnostic criteria used was not described. Filatov et al\textsuperscript{25} reported the case of a 74-year-old man who was COVID-19 positive and presented with encephalopathy. The CT scan of head and cerebrospinal fluid (CSF) studies were negative for any infection. EEG showed evidence of encephalopathy, focal temporal lobe dysfunction, and possible elliptogenicity. Chen et al\textsuperscript{31} in a retrospective study of the clinical characteristics of 113 COVID-19 patients from China, documented hypoxic encephalopathy in 20 patients.

Acute hemorrhagic necrotizing encephalopathy (ANE)
Poyiadji et al\textsuperscript{29} reported the case of a female in her late 50s who presented with altered mental status (AMS), besides fever and cough. Polymerase chain reaction (PCR) assay was positive for COVID-19 and negative for Herpes Simplex Virus 1 and 2, West Nile and Varicella Zoster Virus. Noncontrast CT scan of the head showed symmetric hypo-attenuation within the bilateral medial thalami and MRI demonstrated hemorrhagic rim enhancing lesions within the bilateral thalami, medial temporal lobes, and sub insular regions with a normal CT angiogram and CT venogram. Based on these findings the patient was diagnosed with acute hemorrhagic necrotizing encephalopathy (AHNE) and was treated with intravenous immunoglobulins (IV IgG) but the outcome was not mentioned. ANE is a rare complication of viral infections like influenza. The proposed mechanism is likely due to cytokine storm which results in disruption of blood brain barrier and damage to the brain parenchyma.

Encephalitis
The first confirmed case of COVID-19 associated viral meningo-encephalitis was reported by Moriguchi et al from Japan\textsuperscript{27}. A 24 Years old male presented with fever followed by seizure and unconsciousness. He had neck stiffness. CT scan brain which was normal. CT chest revealed patchy opacities. PCR assay from nasopharyngeal swab was negative but CSF sample was positive for COVID-19. The Diffusion weighted images (DWI) showed hyperintensity along the wall of inferior horn of right lateral Ventricle. Fluid-attenuated inversion recovery (FLAIR) images showed hyperintense signal changes in the right mesial temporal lobe and hippocampus with slight hippocampal atrophy mainly on right mesial lobe and hippocampus. There was no post contrast enhancement. The authors concluded that imaging findings were suggestive of right lateral ventriculitis and encephalitis. This case and presentation should alert clinicians regarding the neuroinvasive potential of COVID-19 and encephalitis like presentation.

Cerebrovascular disease
Sharifi et al\textsuperscript{30} from Iran reported a case of intracranial bleeding resulting in CVA in a 79 Years old COVID-19 positive male. He was admitted in the emergency in a semi-conscious state (Glasgow Coma Scale 7/15) with history of fever and cough. On examination there was, bilateral extensor planter response with coarse crepitation in left lower zones. PCR assay from nasopharyngeal secretion was positive for COVID-19. CT scan chest showed ground glass opacity suggestive of viral pneumonia. CT scan brain revealed a massive bleed within the right hemisphere with intraventricular and subarachnoid extension. This gentleman was neither a known hypertensive nor on any anticoagulants that could have caused this event. The platelets and PT/INR on admission were normal. The authors hypothesized that brain ACE II receptors could be involved in COVID-19 infection and its dysfunction, leading to disruption of autoregulation as well as blood pressure spikes due to arterial wall rupture. Another aspect that is difficult to explain is the near normal blood pressure in this case at the time of admission.

Mao and colleagues\textsuperscript{17} reported six case of CVA in their cohort of 214 patients. There were five ischemic and one case of hemorrhagic stroke. The French cohort had three cases of ischemic strokes which were detected on neuroimaging when the patients underwent imaging for encephalopathy.\textsuperscript{19} The patients did not have focal neurological signs. Probably the symptoms were masked due to presence of encephalopathy, but it highlights the importance of neuroimaging in evaluation of such cases. However more evidence is needed to establish a causal relationship between stroke and COVID-19.

Acute myelitis
Zhao et al\textsuperscript{33} reported acute myelitis in a 66-year-old male from Wuhan city who presented with fever and
body aches. During the admission he developed acute flaccid paralysis of bilateral lower limbs, sensory level at T-10 with urinary and bowel incontinence. CT scan chest confirmed patchy pneumonia and PCR for nasopharyngeal secretion was positive for COVID-19 infection. His serology for all other organism was negative. He was treated empirically with IVIG, steroids, antibiotics and antiviral. The response to treatment was good and he was discharged to an isolation facility for further rehabilitation. The authors attributed acute myelitis to the cytokine storm and overactive inflammatory response as evident by high levels of serum ferritin, C-reactive protein, Serum Amyloid-A and Interleukin-6 levels.

A major limitation of this case report is the lack of CSF PCR for coronavirus and MRI imaging of spine due to epidemic in Wuhan city.

Headache and dizziness

Headaches and dizziness are a nonspecific and minor symptoms of many diseases. They have been reported as minor symptoms associated with presentation of COVID-19 in different reports. The incidence ranges from 3 to 12.1%\textsuperscript{21, 35, 36}. The detailed mechanism and pathophysiology has not been discussed in any of these reports.

Peripheral nervous system manifestation

Anosmia and ageusia

Yan et al\textsuperscript{37} from USA, documented chemosensory dysfunction in 59 COVID-19 positive and 203 COVID-19 negative patients from a single center using an internet based cross sectional survey. They demonstrated that the smell and taste dysfunction was higher in the COVID-19 positive cases as compared to the negative cases (smell loss: 68% vs. 16 % and taste loss: 71% vs. 17%, p<0.001). Most of the patients in this study were ambulatory, did not need hospitalization and none required mechanical ventilation. They hypothesized that probably in ambulatory COVID-19 patients virus spreads via the nasal route as compared to the seriously ill patients in which the spread is most likely pulmonary. Bagheri et al\textsuperscript{38} attempted to find a correlation between increased incidence of anosmia. They found significant correlation between anosmia and COVID-19 positivity in different provinces of Iran (Spearman correlation coefficient: 0.87, p-Value <0.001). Furthermore, those with anosmia were more likely to have dysgeusia and without typical fever/cough/dyspnea symptoms. In contrast the study by Mao et al\textsuperscript{17} in their cohort of 214 Chinese patients reported impairment of taste in 12 (5.6%) and impairment of smell in 11 (5.1%) patients only. Anosmia and taste dysfunction were not reported in the French cohort of COVID-19 patients.

Guillain-Barre syndrome (GBS) and variants

Few cases of COVID-19 associated GBS and its variants have been reported from China, Iran, Italy and Spain. Zhao et al\textsuperscript{39} reported the first case of GBS in a 61 years old female who presented with acute weakness of both legs and severe fatigue, progressing within 1 day. Nerve Conduction Studies (NCS) and Electromyography (EMG) were suggestive of demyelinating polyneuropathy. She was treated with IVIG and later on developed respiratory symptoms. She tested positive for COVID-19.

Sedaghat et al\textsuperscript{40} from Iran reported a 61 -Years old diabetic male who had cough, fever and dyspnea two weeks before presenting with ascending paralysis leading to quadriplegia and facial diplegia. NCS/EMG was suggestive of acute motor sensory axonal neuropathy. He was managed with IVIG. Authors have suggested that GBS should be considered as a neurological complication of COVID-19 since respiratory involvement is common in COVID-19 and can be a risk factor for development of GBS.

Virani and colleagues reported GBS in a 54-Years male from USA\textsuperscript{41}. He presented with rapidly progressing ascending paralysis leading to respiratory difficulty. There was no bladder or bowel dysfunction. Reflexes were absent and MRI spine was normal. He had history of diarrhea preceding the acute attack of weakness. He tested positive for COVID-19. He was managed with IVIG and anti-malarial. He responded well and was weaned off from the ventilator. He was discharged to a rehabilitation facility for physical therapy.

Toscano et al\textsuperscript{42} reported five patients with GBS from Northern Italy. Lower-limb weakness and paresthesia were the main presenting features in four patients, followed by facial weakness, ataxia, and paresthesia in one patient. Four had positive PCR from the nasopharyngeal swab on initial visit and fifth one was initially negative but later turned positive. On NCS/EMG 02 patients had features of demyelinating polyneuropathy while three had axonal polyneuropathy.
All the patients were treated with IVIG. It was repeated in 02 patients and one patient had plasma exchange. After one week, only one patient was able to ambulate independently and discharged from the hospital.

Gutiérrez-Ortiz et al described two COVID-19 cases presenting with variants of Guillain-Barré syndrome (GBS) in Madrid, Spain. Their first patient was a 50-year-old man who presented with a two-day history of vertical diplopia, perioral paresthesia, and gait instability and was found to be COVID-19 positive from nasopharyngeal PCR. Examination areflexia, right internuclear ophthalmoparesis, and right fascicular oculomotor palsy consistent with Miller-Fisher syndrome. Brain imaging with MRI and CSF laboratory studies as well as CSF culture failed to show any abnormality. The patient was treated with immunoglobulins (IV IgG) and had resolution of all of the symptoms except for anosmia and ageusia at the time of discharge. Their second patient was a 39-year-old man who presented with acute onset of diplopia and had a positive nasopharyngeal SARS-CoV-19 PCR. Physical examination showed loss of DTR and bilateral abducens palsy, consistent with polyneuritis cranialis. Other blood, CSF studies, and imaging were negative except for leucopenia. The patient received supportive outpatient treatment and had complete recovery.

Further large scale studies are required to prove this causal relationship between COVID-19 and GBS and its variants.

Skeletal muscle injury
Mao et al. reported skeletal muscle injury in 17 [19.3%] patients in the severely ill and 6 [4.8%] patients in the non-severe group. Skeletal muscle injury was defined as patient having myalgia and elevated serum creatine kinase level above 200 U/L. They concluded that it was not clear whether this was due to the direct effect of virus on muscle tissue. The other possible mechanism proposed was the infection-mediated immune response causing elevated pro-inflammatory cytokines in serum resulting in skeletal muscle damage. However, it is important to note that patients in the severely ill group in addition to raised muscle enzymes, also had elevated liver enzymes and deranged renal functions which could have contributed to the this clinical picture. Moreover, no specific diagnostic workup for confirmation like NCS/EMG or muscle histopathology was performed.

Therefore, it is difficult to rule out the possibility of critical illness myopathy and neuropathy in addition to skeletal muscle damage. Guan and co-workers in their retrospective study showed preliminary evidence of skeletal muscle injury associated with COVID-19 infection among 1099 patients from 550 hospitals in mainland China through January 2020. They found the prevalence of myalgias to be 14.9% amongst patients, with the rate increasing with the severity of illness. They also reported higher creatinine kinase (CK) levels greater than 200 U/L among 12.5% of nonsevere and 19% of severe cases. Only 0.2% were caused due to rhabdomyolysis.

Other manifestations
Mao et al. also reported neuralgia in five patients and epilepsy and ataxia in one each, but further details were not mentioned.

Experience of COVID-19 in the National Institute of Neurosciences Bangladesh:
The first case of COVID-19 was detected in Bangladesh on 8th March 2020. Since then till 30th May 2020, 44608 cases have been detected with a death toll of 610. National Institute of Neuroscience and Hospital is a tertiary Neurology referral center, the only of its kind in Bangladesh. It is a 400 bedded Government hospital which is not designated for COVID 19 patients. But with the increase in the number of COVID patients in the country a lot of patients were found to have a positive COVID test during their stay in the hospital.

The COVID test was done in the hospitalized patients based on various symptoms of COVID like fever, cough, respiratory distress in addition to their neurological problem and also suspicious chest x-ray findings and blood count (lymphopenia). The test was done in 191 patients till 27th May of which 53 (27.7%) turned out positive.

The mean age (± SD) of the positive patients were 46.4 (± 25.43) years (range 1 to 85 years) with 62.3% (33) male and 37.7% (20) female with a ratio of M:F 1.65:1. Most of the patients got admitted in the hospital with the complaints of hemiplegia [30 (56.6%)], acute confusional state [12(22.64%)], altered mental state [7(13.20%)], weakness of all four limbs [2(3.77%)], weakness of both lower limbs [1(1.88%)], seizure [1 (1.88%)]. The neurological diagnosis was stroke [29(54.71%)], subdural empyema [1(1.88%)], meningo-encephalitis
Table-II
Summary of literature of neurological manifestations in COVID-19

<table>
<thead>
<tr>
<th>Author</th>
<th>Study design</th>
<th>Sample size</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asadi-Pooya and Simani</td>
<td>Systematic review</td>
<td>Two significant studies of 214 and 221 patients respectively.</td>
<td>25% of patients exhibited CNS manifestations, including headache (13%), dizziness (17%), and acute cerebrovascular problems (3%). 5% of patients developed acute ischemic stroke, 0.5% developed cerebral hemorrhage, and 0.5% had cerebral venous sinus thrombosis.</td>
</tr>
<tr>
<td>Bagheri et al</td>
<td>Cross-sectional</td>
<td>10069 patients with self-reported olfactory dysfunction, with a mean age of 32.5 years.</td>
<td>A significant correlation (Spearman correlation coefficient=0.87, p&lt;0.001) existed between the number of self-reported olfactory disorders and reported COVID-19 patients. 76.24% of participants reported sudden onset of anosmia. 83.38% of these patients also experienced loss of taste.</td>
</tr>
<tr>
<td>Giacomelli et al</td>
<td>Cross-sectional</td>
<td>69 COVID-19 positive patients with a mean age of 60 (50-74).</td>
<td>33.9% (20) of patients reported either anosmia or ageusia, 18.6% (11) reported both. Females more frequently reported lack of taste or smell (52.6% vs 25%).</td>
</tr>
<tr>
<td>Gutiérrez-Ortiz et al</td>
<td>Case report (two patients)</td>
<td></td>
<td>Patient 1: 50-year-old man presented to the emergency room with symptoms of anosmia and ageusia. Two-day history of vertical diplopia, perioral paraesthesias, and gait instability. Patient 2: 39-year-old man was admitted to the ER with ageusia and onset of diplopia.</td>
</tr>
<tr>
<td>Helms et al</td>
<td>Case series</td>
<td>Prospective case series of 58 patients from France with a median age of 63 years.</td>
<td>Neurological complications were seen in 49/58 patients (84%). As assessed by confusion Assessment method for intensive care unit CAM-ICU scale, agitation was the most common symptoms (24/58 (69%) followed by confusion 26/40 (65%). Corticospinal tract signs were present in in 39/58 (67%) and a dysexecutive syndrome at the time of discharge was noted in14/39 (36%).</td>
</tr>
<tr>
<td>Karimi et al</td>
<td>Case report</td>
<td>30-year-old patient presented in the ER with a generalized tonic-clonic seizure, with five more seizures occurring every eight hours.</td>
<td>Findings included drowsiness with disorientation to time, normal CSF findings, and functional deep tendon reflexes. Blood sample revealed WBC = 5500 cells/mL with 26% lymphocytes, 70% neutrophils, and ESR = 35mm/h.</td>
</tr>
<tr>
<td>Lechien et al</td>
<td>Cross-sectional</td>
<td>417 COVID-19 positive patients with a mean age of 36.9 (19-77).</td>
<td>357 patients (85.6%) developed olfactory dysfunction, with 284 (79.6%) with anosmia and 73 (20.4%) with hyposmia. 342 patients (88.8%) developed gustatory dysfunction. There was a significant associated (p&lt;0.001) between olfactory and gustatory dysfunctions. Females were more significantly associated with both dysfunctions (p&lt;0.001).</td>
</tr>
</tbody>
</table>

*table continued*
<table>
<thead>
<tr>
<th>Author</th>
<th>Study design</th>
<th>Sample size</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li et al&lt;sup&gt;18&lt;/sup&gt;</td>
<td>Retrospective study</td>
<td>221 COVID-19 positive patients with a mean age of 53.3 (57-91).</td>
<td>11 patients (5%) were diagnosed with ischemic stroke, 1 (0.5%) with cerebral venous sinus thrombosis, and one (0.5%) with cerebral hemorrhage.</td>
</tr>
<tr>
<td>Lu et al&lt;sup&gt;24&lt;/sup&gt;</td>
<td>Retrospective study</td>
<td>302 COVID-19 positive patients with a mean age of 44.</td>
<td>Eight patients developed encephalopathy. 84 (27%) patients developed systemic or direct brain results that increased their risk for seizures, including hypoxia (40, 13%). Electrolyte disturbances such as hypokalemia (40, 13%), hyponatremia (34, 11%), and hypocalcemia (22, 7%) were observed.</td>
</tr>
<tr>
<td>Mao et al&lt;sup&gt;17&lt;/sup&gt;</td>
<td>Case series</td>
<td>214 COVID-19 positive patients with a mean age of 52.7.</td>
<td>Six (2.8%) patients developed acute cerebrovascular disease, one (0.5%) with epilepsy. Hypoguesia (12, 5.6%) and hyposmia (11, 5.1%) was observed in patients.</td>
</tr>
<tr>
<td>Moriguchi et al&lt;sup&gt;27&lt;/sup&gt;</td>
<td>Case report</td>
<td>24-year-old man found unconscious was brought to the ED with neck stiffness, headache, and fatigue. Patient had transient generalized seizures during transportation.</td>
<td>Findings included hyperintense signals along the portion of the inferior lobe of the right ventricle. Hyperintensity was present in the right mesial temporal lobe and hippocampus. Slight atrophy of the hippocampus was present. Findings suggestive of meningitis/encephalitis.</td>
</tr>
<tr>
<td>Poyiadji et al&lt;sup&gt;29&lt;/sup&gt;</td>
<td>Case report</td>
<td>Patient in her late 50s presented with a three-day onset of cough, fever, and altered mental status.</td>
<td>Non-contrast CT showed hypoattenuation within the bilateral medial thalamic. Brain MRI demonstrated hemorrhagic rim enhancing lesions in three areas: within the bilateral thalami, medial temporal lobes, and subinsular regions. Findings suggested hemorrhagic necrotizing encephalopathy.</td>
</tr>
<tr>
<td>Sharifi-Razavi et al&lt;sup&gt;30&lt;/sup&gt;</td>
<td>Case report</td>
<td>79-year-old patient presented with a three-day cough and loss of consciousness.</td>
<td>Brain CT revealed a serious intercerebral hemorrhage in the right hemisphere, as well as evidence of intraventricular and subarachnoid hemorrhage.</td>
</tr>
<tr>
<td>Zhao et al&lt;sup&gt;39&lt;/sup&gt;</td>
<td>Case report</td>
<td>61-year-old female presented with weakness in both legs and fatigue. Patient was tested for COVID-19 due to a developed dry cough and fever after eight days of weakness.</td>
<td>Neurological exams revealed weakness and areflexia in legs and feet. After three days, muscle strength was 4/5 in both arms and hands, sensation to pinprick and light touch decreased distally. On day 5, nerve conduction studies showed absent F waves and delayed distal latencies. Patient was diagnosed with Guillain-Barré syndrome.</td>
</tr>
<tr>
<td>Zhao et al&lt;sup&gt;33&lt;/sup&gt;</td>
<td>Case report</td>
<td>66-year old man was admitted to the ICU for weakness in the lower limbs and urinary and bowel incontinence, shortly after experiencing fever and fatigue for seven days.</td>
<td>Neurological examination revealed 3/5 strength in the upper extremities and 0/5 strength in the lower extremities. Hyporeflexia was apparent in the lower limbs. Sensations were intact in the arms but impaired in the legs. Findings suggest acute myelitis.</td>
</tr>
<tr>
<td>Guan et al&lt;sup&gt;44&lt;/sup&gt;</td>
<td>Retrospective study</td>
<td>1099 COVID-19 positive patients with a mean age of 47.0 (35.0-58.0).</td>
<td>Creatinine kinase levels observed in 12.5% (67/536) of nonsevere and 19% (23/121) of severe patients. Rhabdomyolysis in two patients (0.2%).</td>
</tr>
</tbody>
</table>
It was not possible to establish whether COVID-19 was a mere coincidence in the perspective of large-scale ongoing community transmission or it has any causal relationship with the diagnosis. Large scale studies are warranted to establish the fact.

**Conclusion:**

It has become clear from the different studies so far published, that COVID-19 has protean of neurological manifestations. Prompt recognition and early institution of therapy will minimize complications. Complications are more common in severely ill patients. Sometimes neurological symptoms may be the only presentation and many a times they can even precede other symptoms. So a high index of suspicion is required for prompt treatment. Large scale study from different parts of the world will lead to a better understanding of the complications which in turn would help in developing consensus regarding better treatment modalities.

**References:**

2. Green A. Li wenliang. The Lancet. 2020 Feb 29; 395(10225):682. DOI: https://doi.org/10.1016/S0140-6736(20)30382-2
5. Publishing research during pandemics: are you vulnerable to the COVID-19 or predatory publishers? J Pak Med Assoc. 2020; 70 (In press)
Neurological Manifestations of COVID-19 patients: An Updated Review and small Observations  
ME Hussain et al.  


